it is the c17 butanoate ester of levonorgestrel and acts as a prodrug of levonorgestrel in the body the drug is at or beyond the phase iii stage of clinical development but has not been marketed at this time it was first described in the literature by the who in 1983 and has been under investigation for potential clinical use since then lng b has been under investigation as a long lasting injectable contraceptive for women a single intramuscular injection of an aqueous suspension of 5 or 10 mg lng b has a duration of 3 months whereas an injection of 50 mg has a duration of 6 months the drug was also previously tested successfully as a combined injectable contraceptive with estradiol hexahydrobenzoate but this formulation was never marketed lng b has been tested successfully in combination with testosterone buciclate as a long lasting injectable contraceptive for men as well lng b may have several advantages over depot medroxyprogesterone acetate including the use of much lower comparative dosages reduced progestogenic side effects like hypogonadism and amenorrhea and a more rapid return in fertility following discontinuation the drug has a well established safety record owing to the use of levonorgestrel